News for Intellia Therapeutics, Inc. (NTLA)

On June 3, 2025, Canaccord Genuity analyst Whitney Ijem has maintained a 'Buy' rating for Intellia Therapeutics (NTLA). However, there is a noteworthy adjustmen

Intellia Therapeutics (NTLA) has experienced a reduction in its price target from $74 to $54 by Canaccord, although the firm maintained its Buy rating on the st

ARK Investment Management, led by Cathie Wood, has expanded its stake in Intellia Therapeutics (NTLA) by purchasing 226,000 shares. This move underscores ARK's

ARK Investment Management, led by Cathie Wood, has recently expanded its holdings by purchasing 201,000 shares of Intellia Therapeutics (NTLA). This strategic a

Market Overview NVIDIA (NVDA) gained attention through strong quarterly results and positive guidance, pushing its stock up by 3.2%. Market focus shifte

Intellia Therapeutics (NTLA) disclosed a significant safety incident related to grade 4 liver transaminase elevation in its Phase 3 MAGNITUDE study. This develo

Key Takeaways: Intellia Therapeutics (NTLA) faces a challenge in its Phase 3 trial but remains committed to its long-term goals. Analysts see significant

Intellia Therapeutics (NTLA) reported a significant development in its Magnitude trial for transthyretin amyloid cardiomyopathy, revealing the first instance of

U.S. stock futures were higher this morning, with the Dow futures gaining around 100 points on Thursday. Shares of HP Inc. HPQ fell sharply in today's pre-mark...

ZeroHedge - On a long enough timeline, the survival rate for everyone drops to zero

Florida-based Zeo Energy Corp. (ZEO) is up over 121 percent in Thursday's pre-market trading. The following are some of the other stocks making big moves in Thursday's pre-market trading.

Shares of NVIDIA Corporation NVDA rose sharply in today's pre-market trading after the company posted first-quarter results. The company reported first-quarter...

Market Analysis by covering: S&P 500, Novavax Inc, Sanofi ADR, Novo Nordisk A/S. Read 's Market Analysis on Investing.com

Intellia Therapeutics (NTLA) has shared encouraging two-year follow-up results from its Phase 1 trial of nexiguran ziclumeran, known as nex-z, aimed at treating

Intellia Therapeutics (NTLA) showcased a 90% reduction in serum TTR maintained for 24 months in the Phase 1 study of nexiguran ziclumeran (nex-z). 14 ou

Intellia Therapeutics, Inc. (NASDAQ:NTLA) BofA Securities 2025 Healthcare Conference May 13, 2025 7:20 PM ETCompany ParticipantsEd Dulac - CFOConference...

On May 12, 2025, Guggenheim analyst Debjit Chattopadhyay reiterated a 'Buy' rating for Intellia Therapeutics (NTLA). Despite maintaining the positive rating, th

Guggenheim has revised its price target for Intellia Therapeutics (NTLA), reducing it from $55 to $45, while maintaining a Buy rating on the stock. The analyst

On May 9, 2025, Citigroup analyst David Lebowitz released an update regarding Intellia Therapeutics (NTLA). The firm has maintained a "Neutral" rating for the c